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Abstract
Background
Severe malaria is a leading cause of acquired neurodisability in Africa and is associated with
reduced nitric oxide (NO) bioavailability. A neuroprotective role for inhaled NO has been
reported in animal studies, and administration of inhaled NO in preterm neonates with respi-
ratory distress syndrome is associated with a 47% reduced risk of cognitive impairment at
two years of age.
Methods
A randomized double-blind placebo-controlled trial of inhaled NO versus placebo as an
adjunctive therapy for severe malaria was conducted in Uganda between 2011 and 2013.
Children received study gas for a maximum 72 hours (inhaled NO, 80 parts per million; room
air placebo). Neurocognitive testing was performed on children<5 years at 6 month follow-
up. The neurocognitive outcomes assessed were overall cognition (a composite of fine
motor, visual reception, receptive language, and expressive language), attention, associa-
tive memory, and the global executive composite. Main outcomes were attention, associa-
tive memory, and overall cognitive ability.
Results
Sixty-one children receiving iNO and 59 children receiving placebo were evaluated. Forty-
two children (35.0%) were impaired in at least one neurocognitive domain. By intention-to-
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treat analysis, there were no differences in unadjusted or unadjusted age-adjusted z-scores
for overall cognition (β (95% CI): 0.26 (-0.19, 0.72), p = 0.260), attention (0.18 (-0.14, 0.51),
p = 0.267), or memory (0.14 (-0.02, 0.30), p = 0.094) between groups by linear regression.
Children receiving inhaled NO had a 64% reduced relative risk of fine motor impairment
than children receiving placebo (relative risk, 95% CI: 0.36, 0.14–0.96) by log binomial
regression following adjustment for anticonvulsant use.
Conclusions
Severe malaria is associated with high rates of neurocognitive impairment. Treatment with
inhaled NO was associated with reduced risk of fine motor impairment. These results need
to be prospectively validated in a larger study powered to assess cognitive outcomes in
order to evaluate whether strategies to increase bioavailable NO are neuroprotective in chil-
dren with severe malaria.
Trial registration
ClinicalTrials.gov Identifier: NCT01255215.
Introduction
In sub-Saharan Africa, severe malaria leads to long-term neurocognitive deficits in 26% of sur-
vivors, making it a leading cause of acquired neurodisability [1], and the most common cause
of disability-adjusted life-years (DALYs) in Africa following HIV/AIDS [2]. Deficits have been
observed in attention, memory, speech and language with fewer studies reporting deficits in
motor skills, visual spatial skills, executive function, somatosensory discrimination and learn-
ing [1, 3–12]. Neurologic deficits are typically observed in the first six months after the episode
[13], with more subtle cognitive deficits persisting or emerging up to eight years post-illness
[9].
Neurocognitive deficits after severe malaria have been associated with coma depth and
duration, seizures, and neurological abnormalities at discharge [1, 5, 6, 8, 10, 11, 14]. Other
factors associated with neurocognitive deficits include hypoglycemia, severe malnutrition, fea-
tures of intracranial hypertension, and elevated cerebrospinal fluid tumor necrosis factor [1,
10, 14, 15].
Severe malaria is associated with decreased nitric oxide (NO) bioactivity as a result of NO
production [16, 17]; inhibition of endothelial NO synthase (NOS) by endogenous inhibitors
(e.g. asymmetric dimethyl arginine) [18]; reduced plasma L-arginine (a substrate for NOS)
due to increased sequestration and consumption of intraerythrocytic arginine by the para-
site; and NO quenching by cell-free hemoglobin [17, 19–22]. Administration of exogenous
L-arginine in adults with severe malaria was associated with improved endothelial recovery
[17], and delivery of inhaled NO (iNO) in experimental cerebral malaria was associated with
prolonged survival and preserved blood brain barrier integrity [23]. Inhaled NO has an
established safety record and is approved for use in neonates with hypoxic respiratory failure
[24].
Based on the hypothesis that iNO is neuroprotective, cognitive outcomes were evaluated at
six month follow-up as a secondary endpoint of a randomized controlled trial evaluating iNO
as an adjunctive therapy for children with severe malaria [25].
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Methods
Trial design
This was a prospective, parallel arm, randomized, double-blind placebo-controlled, clinical
trial of iNO versus placebo among children with severe malaria treated with parenteral artesu-
nate at Jinja Regional Referral Hospital in eastern Uganda where malaria accounts for over
30% of admissions. Children were eligible if they were aged 1–10 years with a positive three
band malaria rapid diagnostic test (First Response Malaria Ag. (pLDH/HRP2) Combo Rapid
Diagnostic Test, Premier Medical Corporation Limited, India), had features of severe malaria
(repeated seizures, prostration, impaired consciousness, or respiratory distress), and were will-
ing and able to complete follow-up [25]. Exclusion criteria included baseline methemoglobine-
mia (>2%), history of chronic illness, and severe malnutrition [25].
Interventions
Simple randomization was performed using a computer-generated list created prior to study
commencement [25]. Treatment assignment was recorded on paper and kept in sequentially
numbered, sealed, opaque envelopes and stored in a locked cabinet accessible only to the un-
blinded study team. Following patient stabilization and informed consent, the next envelope
was drawn by an un-blinded investigator. All children were treated with intravenous artesu-
nate according to the Ugandan Ministry of Health standard of care. Participants in the iNO
group received the gas at a starting concentration of 80ppm administered continuously via
non-rebreather facemask for a maximum period of 72 hours [25]. iNO was indistinguishable
from placebo in appearance and delivery system (mask, tubing, vehicle air). An un-blinded
monitoring team initiated and monitored study gas while blinded nurses and clinicians were
out of the room. Flow-meters and monitoring devices were located in locked, opaque boxes,
accessible only to the un-blinded study team.
Outcomes
Neurocognitive functioning was a pre-specified secondary outcome of the study [26]. The pri-
mary outcome was the longitudinal recovery of angiopoietin-2, as previously published [25].
Overall cognitive ability was assessed by the Mullen Scales of Early Learning [27], attention
was assessed by the Early Childhood Vigilance Test [28], associative memory was assessed by
the Color Object Association Test [29], and executive function was assessed by the Behavior
Rating Inventory of Executive Function [30]. The Mullen Scales, Color Object Association
Test and Early Childhood Vigilance Test have been used in Ugandan children <5 years to
study the long-term effect of severe malaria on cognition [6].
The Mullen Scales assess cognition and motor skills from birth to 68 months and is com-
posed of five scales: i) gross motor, ii) fine motor, iii) visual reception, iv) receptive language,
and v) expressive language. Cognitive ability is a summation of scores from four of five scales
(excludes gross motor). Neurocognitive impairment is defined as a z-score-2 in the follow-
ing domains: fine motor, gross motor, visual reception, receptive language, and expressive lan-
guage (from the Mullen Scales); associative memory (from the Color Object Association Test);
and attention (from the Early Childhood Vigilance Test, ECVT). The summary score from all
the items in the Behavior Rating Inventory of Executive Function is the Global Executive Com-
posite, our measure of Executive Function [30]. A positive z-score in the Behavior Rating
Inventory of Executive Function is associated with worse executive function, so impairment in
the Global Executive Composite is defined as a z-score2.
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Cognitive testing was performed on children<5 years so the same set of neuropsychological
tests could be used for the entire cohort. Based on the intensity of malaria transmission and pat-
tern of illness in Jinja, the majority children presenting with severe malaria are<5 years old, and
testing a limited sub-set of older children using a different set of tools would have limited value as
tests cannot be directly compared when different assessment tools are used. Each child was
assessed by a single neurocognitive tester blinded to treatment group and testing was performed
according to the test manuals. For quality control assessment, every five ECVT videos were re-
coded by the supervisor to ensure scores were within 10 seconds of each other. Once 30 videos
were coded without problem, the coder was deemed proficient and coded videos independently.
Statistical analysis
Inclusion of 180 children with severe malaria was needed to show with 80% power and 95%
confidence a 50% difference in the rate of change in Ang-2 over hospitalization [25]. Age
adjusted z-scores were generated for each of the outcomes as previously described [1]. Age
adjusted z-scores for the neurocognitive outcomes were compared between the groups using
linear regression adjusting for co-variates with a p<0.200 by bivariate analysis. Log binomial
regression was used to estimate the relative risk between treatment arm and impairment across
neurocognitive domains adjusting for anti-convulsant use. To compare z-scores with recovery
times we used Spearman’s non-parametric correlation. Statistical analyses were done with
IBM1 SPSS statistics for Windows, version 20.0 (IBM Corp., Armonk, N.Y., USA) and Stata
version 14.0 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: Stata-
Corp LP). An alpha of less than 0.05 was considered statistically significant. To adjust for
multiple comparisons we used the Bonferroni correction and an adjusted alpha of 0.006 is
required for significance based on 9 neurocognitive domains assessed (attention, memory,
executive function, cognition, and five cognitive sub-scales).
Ethical considerations
Written informed consent was obtained from guardians of study participants. Ethical approval
was granted by the Institutional Review Boards at Makerere University School of Medicine,
University Health Network, Toronto, and the Uganda National Council of Science and Tech-
nology. The trial is registered (ClinicalTrials.gov Identifier: NCT01255215).
Results
Participants were recruited between July 2011 and June 2013 and followed until January 2014
according to the study protocol. Nineteen of the original 180 children were not eligible for
neurocognitive follow up as they were greater than five years of age. The flow of study partici-
pants is shown in Fig 1. The percentage of children completing neurocognitive testing at 6
months was comparable between groups (iNO, n = 61/70, 87%; placebo, n = 59/66, 89%). The
time to neurocognitive evaluation was 26.5 weeks in the iNO group versus 26.3 weeks in the
placebo group (p = 0.77).
There was no difference in age, sex, weight-for-age z-score, socioeconomic status, parental
education, and child’s education between arms (Table 1). The number of presenting features
of severe malaria was similar between trial arms (Table 1). Children randomized to iNO were
more likely to receive an anticonvulsant during hospitalization (diazepam and/or phenobarbi-
tone, p = 0.013). The mean duration of time on study gas was comparable between groups
with children receiving iNO for 61.4 hours versus hours 63.0 in the placebo group (p = 0.496).
At discharge, surviving children had a neurologic exam; 8 (9.8%) children in the placebo
group and 5 (6.2%) children in the iNO group had objective neurologic abnormalities
Inhaled nitric oxide and cognition in severe malaria: A randomized trial
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(p = 0.40). Abnormalities included inability to sit (2), unilateral weakness (3), abnormal tone
(2), extra-ocular muscle palsy (2), visual defects (3), seizure disorder (2), and inability to speak
(2). Computed tomography of the head was performed in 4 patients and showed global atro-
phy in 2 cases, suggestive of antecedent insult. Full recovery to baseline neurologic function by
day 14 was apparent in only one patient.
Fig 1. Flowchart of study population.
https://doi.org/10.1371/journal.pone.0191550.g001
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Factors associated with neurologic abnormality and neurocognitive
outcome
The proportion of children with a neurologic abnormality at discharge and neurocognitive
impairment at 6 months follow-up were 8.0% and 35.0% respectively. Children with neuro-
logic abnormality at discharge were more likely to be comatose (p = 0.007), had a lower BCS
at admission (p<0.0001), took longer to localize pain (p = 0.003) and regain consciousness
(p<0.0001) than children with a normal neurologic exam at discharge. Neurologic abnormal-
ity at discharge was associated with impairments in fine and gross motor skills (p<0.001 for
both), receptive language (p = 0.001), expressive language (p = 0.005), overall cognition
(p = 0.008), and executive function (p = 0.001). Neurologic abnormality at discharge was
Table 1. Demographic characteristics of follow-up cohort.
iNO (n = 61) Placebo (n = 59) P value
Admission Characteristics
Age (years) 2.1 (1.4, 2.7) 2.1 (1.4, 3.0) 0.545
Sex (n, % female) 21 (34.4) 29 (49.2) 0.102
Weight for age z-score -0.6 (-1.7, 0) -1.0 (-1.8, -0.4) 0.122
Height, cm 78 (72, 87) 80 (72, 87) 0.745
History of fever, days 3 (2, 5) 3 (2, 4) 0.495
Respiratory rate 48 (40, 62) 50 (39, 60) 0.875
Coma on admission (BCS<3) (n, %) 38 (62.3) 31 (52.5) 0.280
Hyperlactatemia on admission (lactate>5mmol/L) (n, %) 14 (23.7) 23 (39.0) 0.074
Severe anemia on admission (n, %) 37 (60.7) 40 (67.8) 0.415
Hypoglycemia (glucose <2.2mmol/L) (n, %) 0 (0.0) 2 (3.4) 0.240
Hemoglobin, g/dL 5.4 (3.6, 6.7) 4.5 (3.1, 6.5) 0.295
Lactate, mmol/L 3.2 (2.1, 4.6) 3.9 (2.3, 7.9) 0.093
Glucose, mmol/L 6.7 (5.6, 8.5) 6.9 (5.6, 8.7) 0.688
Creatinine, umol/L 29 (21, 36) 32 (25, 42) 0.051
Number of severe malaria criteriaa 4 (3, 6) 5 (3, 5) 0.619
Pretreatment with antibiotics (n, %) 31 (54.4) 26 (45.6) 0.349
Pretreatment with antimalarials (n, %) 36 (60.0) 38 (64.4) 0.620
Household Characteristics
Socioeconomic status score 9 (8, 11) 9 (7, 10) 0.151
Maternal education (n, %) 0.357
Primary 6 or lower 24 (40.7) 22 (39.3)
Primary 7 13 (22.0) 10 (17.9)
Secondary or higher 18 (30.5) 17 (30.4)
Not known 4 (6.8) 7 (125)
Paternal education (n, %) 0.931
Primary 6 or lower 12 (20.0) 12 (21.1)
Primary 7 14 (23.3) 12 (21.1)
Secondary or higher 33 (55.0) 31 (54.4)
Not known 1 (1.7) 2 (3.5)
Child’s education, pre-school (n, %) 4 (6.7) 2 (3.5) 0.680
Data presented as median (IQR)
a Coma, respiratory distress, convulsions, prostration, hypoglycemia, hyperlactatemia, severe anemia, shock, acute
kidney injury, jaundice.
Analysed using Wilcoxon rank sum, or Pearson Chi-Square or Fisher’s exact (as appropriate).
https://doi.org/10.1371/journal.pone.0191550.t001
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associated with a greater number of cognitive domains impaired (p<0.001, Chi-Square test-
for-trend).
As this study enrolled children with multiple manifestations of severe malaria, we investi-
gated the nature of neurologic abnormality and cognitive impairment in children with and
without coma. Children with coma on admission had lower mean z-scores for gross and fine
motor functioning (all p<0.05) compared to children with a BCS>2. There were no differ-
ences in the mean z-scores in other domains assessed or in rates of neurocognitive impairment
according to coma status on admission (p>0.05 for all domains assessed). Treatment with
anticonvulsants was not associated with neurologic deficit at discharge or the presence of any
cognitive deficit at 6 months follow up. Administration of anticonvulsants was associated with
worse z scores in expressive language (mean difference (95% CI, -0.25 (-0.42 to -0.08),
p = 0.0498), but was not associated with differences in the other cognitive domains assessed.
We investigated the association between clinical recovery times and cognitive outcomes at
six months. Children receiving iNO had a significantly longer duration of hospitalization and
took longer to achieve a BCS of 5 than children in the placebo arm (median (IQR), p-value:
duration of hospitalization, iNO, 79 hours (62–91), placebo, 63 hours (59, 85), p = 0.033; time
to reach BCS 5, iNO, 15.3 hours (9.3, 29.5), placebo, 12.0 (6.0, 22.7), p = 0.051) (Table 2).
There was no difference in other recovery times between treatment arm.
In the placebo arm, prolonged clinical recovery times were associated with worse cognitive
functioning. Increased time to sit unsupported was associated with lower attention scores
(rho, p-value: -0.33, p = 0.02) and worse gross motor functioning (-0.36, p = 0.006). Time to
localize pain was inversely associated with overall cognitive score (-0.32, p = 0.01), gross motor
functioning (-0.27, p = 0.04), receptive language (-0.26, p = 0.04), and expressive language
(-0.26, p = 0.05). Increased duration of hospitalization was associated with worse gross motor
functioning (-0.27, p = 0.04). In children receiving iNO, there was an inverse association
between the duration of hospitalization and fine motor functioning (-0.34, p = 0.007). Compli-
cations and clinical recovery times between groups are shown in Table 2.
Effect of iNO versus placebo on neurocognitive outcome
By intention-to-treat analysis iNO was not associated with improved overall cognition, mem-
ory, or attention (p>0.05) in age-adjusted z scores (Table 3, Table 4). In a linear regression
analysis adjusting for sex, socioeconomic status, venous lactate, creatinine and anticonvulsant
use between groups, there was no difference in age-adjusted z scores by treatment arm (p>
0.05, Table 4). However, treatment with iNO was associated with less fine motor impairment
than children receiving placebo (iNO, n = 5 (8.2%); placebo, n = 13 (22%), p = 0.03), corre-
sponding to a 64% reduced relative risk of fine motor impairment when receiving iNO (RR,
95% CI: 0.36, 0.14–0.96) adjusting for anticonvulsant use (p = 0.04, Table 3). Further, children
in the placebo arm were more likely to have multiple domains impaired with 25.4% of children
in placebo arm having two or more domains impaired compared to 11.5% in the nitric oxide
group (p = 0.048 by Pearson’s Chi Square). Inhaled nitric oxide was associated with a 58%
reduced relative risk of having multiple domains impaired (RR, 95% CI: 0.42, 0.18–0.97,
p = 0.04, Table 3) following adjustment for anticonvulsant use. The proportion of children
impaired in other domains assessed was comparable between arms (Table 3).
Discussion
This is the first randomized controlled trial to investigate neurocognitive outcomes in children
receiving an adjunctive therapy for severe malaria. There proportion of children with neuro-
cognitive impairment at follow-up was high with 35% of children tested demonstrating
Inhaled nitric oxide and cognition in severe malaria: A randomized trial
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cognitive impairment in at least one domain. The impact of iNO on neurologic and neurocog-
nitive outcomes was analyzed by intention-to-treat analysis. There were no differences in age
adjusted z-scores between children receiving iNO vs. placebo looking at individual neurocog-
nitive domains (e.g. attention, fine/gross motor skills, expressive/receptive language, associa-
tive memory) or composite measures (e.g. overall cognition, executive function), but children
receiving iNO were less likely to have fine motor impairment (p = 0.04), although the effect
was not significant following adjustment for multiple comparisons. Collectively, these data
show there is a high risk of neurocognitive impairment following severe malaria even when
treated with intravenous artesunate and highlight the importance of including cognitive test-
ing when evaluating therapies for severe malaria.
Table 2. Complications, recovery times, and neurocognitive outcome by treatment arm.
iNO (n = 61) Placebo (n = 59) P
Cotreatments
Blood transfusion 47 (77.1) 45 (76.3) 0.920
Antibiotic
Ceftriaxone 57 (95.0) 51 (89.5) 0.262
Metronidazole 4 (7.0) 3 (5.9) 0.811
Other 5 (8.2) 7 (12.3) 0.463
Anticonvulsant
Diazepam 26 (45.6) 15 (30.6) 0.114
Phenobarbitone 20 (33.9) 12 (20.3) 0.098
Diazepam or Phenobarbitone 35 (58.3) 21 (35.6) 0.013
Antipyretic
Paracetamol 46 (76.7) 49 (83.1) 0.386
Diclofenac 6 (10.9) 5 (10.4) 0.936
Complications
Convulsions persisting >6h after admission 12 (19.7) 10 (16.9) 0.815
Develop severe anemiaa 9 (34.6) 3 (16.7) 0.303
Develop hemoglobinuriaa 0 (0.0) 3 (5.9) 0.118
Treatment discontinued for acute kidney injuryb 3 (4.9) 0 (0.0) 0.244
Persistent acidosis at 12 hours (lactate>5mmol/L) 8 (15.1) 4 (7.5) 0.359
Recovery Times
Time to first feed, hours 19.0 (12.1, 37.2) 13.6 (8.5, 26.2) 0.073
Time to fever resolution, hours 8.0 (0, 32.0) 9.0 (0, 28.5) 0.920
Time to localize pain, hours 8.2 (0, 15.9) 5.7 (0, 12.3) 0.172
Time to BCS 5, hours 15.3 (9.3, 29.5) 12.0 (6.0, 22.7) 0.051
Time to first sit, hours 34.3 (17.5, 60.5) 32.0 (15.3, 62.2) 0.070
Duration of hospitalization 79.0 (62.0, 90.5) 63.0 (59.0, 84.5) 0.033
Neurocognitive Outcomes
Neurologic abnormality on discharge 4 (6.6) 5 (8.5) 0.741
Continuous data analyzed using Wilcoxon rank sum test otherwise indicated; categorical variables analyzed using Pearson’s Chi-Square test or Fisher’s exact, as
appropriate.
a Assessed only in children without these disorders on admission.
b Acute kidney injury was defined as follows: Serum creatinine >1.5 × upper limit of normal (children age 1–2) or >2.0 × upper limit of normal (age 2–10) AND an
abrupt (within 48 h) reduction in kidney function: (1) an absolute increase in serum creatinine of 26.4 μmol/l; or (2) a percentage increase in serum creatinine of
50%.
https://doi.org/10.1371/journal.pone.0191550.t002
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Table 3. Differences in mean age-adjusted z scores and cognitive impairment by study arm.
iNO (n = 61) Placebo (n = 59) Effect Size P
Age-adjusted z-scores Mean difference (95% CI)
Attention (ECVT) 0.70 (0.86) 0.52 (0.91) -0.18 (- 0.51 to 0.14) 0.268
Associative Memory (COAT) -0.04 (0.41) -0.14 (0.49) -0.14 (-0.30 to 0.02) 0.095
Global Executive Composite (BRIEF) 0.59 (1.00) 0.69 (1.41) 0.10 (-0.34 to 0.55) 0.653
Overall Cognitive Ability (Mullen) -0.61 (1.09) -0.87 (1.41) -0.26 (-0.72 to 0.20) 0.262
Fine Motor -0.58 (1.23) -0.99 (1.68) -0.41 (-0.94 to 0.12) 0.131
Gross Motor -0.08 (1.76) -0.14 (2.00) -0.06 (-0.75 to 0.62) 0.852
Visual Reception -0.91 (1.35) -1.10 (1.56) -0.19 (-0.72 to 0.33) 0.470
Receptive Language -0.70 (1.09) -0.95 (1.51) -0.25 (-0.73 to 0.22) 0.300
Expressive Language -0.03 (0.78) -0.10 (0.81) -0.06 (-0.35 to 0.22) 0.665
Impairment Relative Risk (95% CI) P
Attention (ECVT) 0 (0.0%) 1 (1.8%) — —
Associative Memory (COAT) 0 (0.0%) 0 (0.0%) — —
Global Executive Composite (BRIEF) 5 (8.3%) 8 (13.6%) 0.47 (0.17, 1.36) 0.165
Overall Cognitive Ability (Mullen) 5 (8.2%) 8 (13.6%) 0.64 (0.22, 1.91) 0.428
Fine Motor 5 (8.2%) 13 (22.0%) 0.36 (0.14, 0.96) 0.042
Gross Motor 3 (4.9%) 5 (6.4%) 0.76 (0.17, 3.35) 0.712
Visual Reception 15 (24.6%) 14 (23.7%) 0.99 (0.52, 1.90) 0.985
Receptive Language 4 (6.6%) 10 (16.9%) 0.39 (0.13, 1.21) 0.103
Expressive Language 1 (1.6%) 1 (1.7%) 0.96 (0.06, 16.10) 0.976
Any domain impaired 18 (29.5%) 24 (40.7%) 0.69 (0.42, 1.14) 0.150
Multiple domains impaired 7 (11.5%) 15 (25.4%) 0.42 (0.18, 0.97) 0.042
Main outcomes are in bold.
Data are presented as mean (SD) or n (%) with analysis by Student’s t-test or a log binomial model adjusting for anticonvulsant use
Impairment is defined as less than -2SD in age-adjusted z-scores for the early learning composite (encompassing fine/gross motor, visual reception, receptive/expressive
language), attention, and associative memory, or greater than 2SD for the global executive function.
 A positive z-score in the Global Executive Composite (BRIEF) is associated with worse executive function.
https://doi.org/10.1371/journal.pone.0191550.t003
Table 4. Regression models of unadjusted and adjusted age-adjusted z scores by study arm.
Unadjusted Model Adjusted Model1
Beta (95% CI) P Beta (95% CI) P
Attention (ECVT) 0.18 (-0.14, 0.51) 0.267 0.18 (-0.18, 0.54) 0.333
Associative Memory (COAT) 0.14 (-0.02, 0.30) 0.094 0.12 (-0.07, 0.30) 0.193
Global Executive Composite (BRIEF) -0.10 (-0.55, 0.34) 0.652 -0.28 (-0.74, 0.18) 0.228
Overall Cognitive Ability (Mullen) 0.26 (-0.19, 0.72) 0.260 0.33 (-0.20, 0.85) 0.219
Fine Motor 0.41 (-0.12, 0.94) 0.129 0.50 (-0.11, 1.11) 0.110
Gross Motor 0.06 (-0.62, 0.74) 0.852 0.37 (-0.39, 1.14) 0.336
Visual Reception 0.19 (-0.33, 0.72) 0.469 0.26 (-0.35, 0.86) 0.405
Receptive Language 0.25 (-0.22, 0.73) 0.297 0.21 (-0.34, 0.76) 0.448
Expressive Language 0.06 (-0.22, 0.35) 0.665 0.14 (-0.18, 0.46) 0.391
Main outcomes are in bold.
1 Data analyzed by linear regression with age-adjusted z scores as dependent variables and sex, socioeconomic status,
venous lactate, anticonvulsant use, and creatinine as independent variables.
 A positive z-score in the Global Executive Composite (BRIEF) is associated with worse executive function.
https://doi.org/10.1371/journal.pone.0191550.t004
Inhaled nitric oxide and cognition in severe malaria: A randomized trial
PLOS ONE | https://doi.org/10.1371/journal.pone.0191550 January 25, 2018 9 / 13
A neuroprotective role for iNO has been reported in animal studies [31–33], and adminis-
tration of iNO in preterm neonates with respiratory distress syndrome is associated with a
47% reduced risk of cognitive impairment at two years of age [24]. In this study we observed
reduced fine motor impairment in children randomized to iNO supporting the hypothesis
that iNO is neuroprotective in severe malaria; however, as this study was not powered for neu-
rocognitive outcomes, it is likely we were underpowered to detect differences across multiple
domains. Further, in this study a heterogeneous group of children with severe malaria with
and without neurologic manifestations were included. The majority of studies assessing cogni-
tive impairments following severe malaria have focused on children with neurologic signs (e.g.
coma, multiple seizures, and decreased consciousness). Unexpectedly, we observed only mod-
est differences in cognitive performance in children who presented with coma versus those
without; suggesting cognitive impairment is common even in children without clear neuro-
logic manifestations at presentation. These data are consistent with a recent report document-
ing cognitive impairment following severe malarial anemia [6].
In the original trial report, there were trends of lower mortality and prolonged coma dura-
tion times in children randomized to iNO, and children receiving iNO were more likely to
receive anticonvulsants [25]. As the study was not powered to detect differences in mortality, it
raised questions of whether iNO led to better survival but was associated with increased coma
duration, neurologic sequelae and cognitive impairment. The data presented herein do not
support this. While we observed increased duration of hospitalization and prolonged recovery
to BCS 5 in children receiving iNO in the subset of children tested at 6 months follow up, chil-
dren receiving iNO had less fine motor impairment and were less likely to have multiple
domains impaired than children receiving placebo. Although the neurocognitive difference
was not significant following adjustment for multiple comparisons, it is important to note that
the study was not powered for neurocognitive outcomes.
Limitations of this study include a relatively short follow-up period with a single cognitive
assessment. A longer follow-up period would permit an evaluation of children as they start
school and have greater cognitive demands. This is important as cognitive deficits have been
shown to persist over at least a year of follow up [6]. The sample size for this study was calcu-
lated based on estimated longitudinal changes in angiopoietin-2 over hospitalization. We were
likely underpowered to detect more subtle cognitive differences between trial arms, particu-
larly as the population consists of a heterogeneous group of children with different manifesta-
tions of severe malaria. As cognitive assessment tools are validated within specific age ranges
we were limited to evaluating neurocognitive function to children <5 years of age given the
mean age of children presenting with severe malaria in our population.
Strengths of this study include the randomized study design where all clinicians, parents,
and neuropsychological testers were blinded to the treatment group. Further, a comprehensive
set of neurocognitive assessment tools that have been validated for use in Ugandan children
were used to assess neurocognitive recovery. Importantly, in this study we show neurocogni-
tive impairment was common in a heterogeneous group of children with severe malaria
treated with artesunate. Additional studies to validate these studies are needed and should con-
sider including a longer period of follow up and larger sample size to delineate the risk of cog-
nitive impairment across common manifestations of severe malaria in children.
Conclusion
Our data suggest iNO may be neuroprotective in Ugandan children with severe malaria with
improvements in fine motor functioning in children receiving iNO. Although these data
require validation, this study is the first to suggest a beneficial long-term impact associated
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with an adjunctive therapy in severe malaria. Cognitive impairment was common among all
children, suggesting additional studies are required to define the extent and the mechanisms
that underlie cognitive impairment in severe malaria. As more data become available on the
frequency and breadth of cognitive impairment across the spectrum of severe malaria, better
estimates on the long term impact of severe malaria will emerge. Given the impact of malaria
on DALYs in Africa, it is a public health imperative that treatments be identified to limit neu-
rodisability (e.g. adjunctive neuroprotective therapies), and promote neurocognitive recovery.
The high risk of cognitive impairment in children treated with artesunate strongly support
inclusion of neurocognitive assessment in trials assessing adjunctive therapies in children with
severe malaria.
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